Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Abortion, Induced | 21 | 2024 | 90 | 5.650 |
Why?
|
| Pregnancy | 39 | 2024 | 1737 | 2.220 |
Why?
|
| Robotics | 5 | 2024 | 42 | 2.100 |
Why?
|
| Contraception | 7 | 2023 | 60 | 2.000 |
Why?
|
| Abortion, Spontaneous | 3 | 2022 | 28 | 1.840 |
Why?
|
| Contraception Behavior | 4 | 2020 | 33 | 1.490 |
Why?
|
| Papillomavirus Vaccines | 5 | 2024 | 168 | 1.190 |
Why?
|
| Hawaii | 24 | 2025 | 2004 | 1.090 |
Why?
|
| Postal Service | 3 | 2022 | 12 | 1.080 |
Why?
|
| Intrauterine Devices | 4 | 2020 | 19 | 1.040 |
Why?
|
| Female | 51 | 2025 | 24018 | 0.960 |
Why?
|
| Abortifacient Agents | 3 | 2024 | 11 | 0.930 |
Why?
|
| Gestational Age | 8 | 2024 | 195 | 0.880 |
Why?
|
| Young Adult | 25 | 2025 | 4936 | 0.880 |
Why?
|
| Adolescent | 23 | 2025 | 5950 | 0.850 |
Why?
|
| Contraceptive Agents, Female | 3 | 2020 | 25 | 0.830 |
Why?
|
| Telemedicine | 3 | 2021 | 215 | 0.810 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 680 | 0.800 |
Why?
|
| Uterine Hemorrhage | 4 | 2019 | 14 | 0.780 |
Why?
|
| Fetal Research | 1 | 2022 | 4 | 0.760 |
Why?
|
| Humans | 56 | 2025 | 42163 | 0.760 |
Why?
|
| Fentanyl | 1 | 2022 | 16 | 0.750 |
Why?
|
| Adult | 32 | 2025 | 13458 | 0.750 |
Why?
|
| Home Childbirth | 1 | 2022 | 1 | 0.750 |
Why?
|
| Mercury | 3 | 2024 | 39 | 0.750 |
Why?
|
| Qualitative Research | 6 | 2023 | 526 | 0.720 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2022 | 44 | 0.710 |
Why?
|
| Intrauterine Devices, Medicated | 2 | 2018 | 12 | 0.680 |
Why?
|
| Levonorgestrel | 2 | 2018 | 17 | 0.680 |
Why?
|
| Papillomavirus Infections | 4 | 2024 | 363 | 0.670 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2019 | 172 | 0.650 |
Why?
|
| Pregnancy, Unplanned | 2 | 2020 | 29 | 0.640 |
Why?
|
| Fetal Blood | 3 | 2015 | 48 | 0.640 |
Why?
|
| Choice Behavior | 1 | 2020 | 91 | 0.610 |
Why?
|
| Social Values | 2 | 2016 | 31 | 0.610 |
Why?
|
| Seafood | 3 | 2024 | 24 | 0.600 |
Why?
|
| Insurance, Health | 3 | 2023 | 143 | 0.590 |
Why?
|
| Physicians | 1 | 2020 | 180 | 0.580 |
Why?
|
| Condoms | 1 | 2019 | 148 | 0.580 |
Why?
|
| Attitude to Health | 1 | 2021 | 336 | 0.580 |
Why?
|
| Insurance Coverage | 2 | 2015 | 108 | 0.560 |
Why?
|
| Laminaria | 1 | 2017 | 2 | 0.550 |
Why?
|
| Anesthesia, Obstetrical | 1 | 2017 | 7 | 0.550 |
Why?
|
| Postpartum Period | 1 | 2018 | 91 | 0.530 |
Why?
|
| Reminder Systems | 1 | 2017 | 15 | 0.530 |
Why?
|
| Postnatal Care | 1 | 2017 | 16 | 0.520 |
Why?
|
| Attitude of Health Personnel | 2 | 2017 | 222 | 0.510 |
Why?
|
| Family Planning Services | 2 | 2018 | 34 | 0.510 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2017 | 15 | 0.490 |
Why?
|
| Family Planning Policy | 1 | 2015 | 1 | 0.480 |
Why?
|
| Family Practice | 2 | 2016 | 57 | 0.480 |
Why?
|
| Oxytocin | 3 | 2022 | 24 | 0.470 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2017 | 959 | 0.460 |
Why?
|
| Pediatrics | 1 | 2015 | 69 | 0.450 |
Why?
|
| Diabetes, Gestational | 3 | 2023 | 55 | 0.440 |
Why?
|
| United States | 9 | 2025 | 5072 | 0.430 |
Why?
|
| Medicaid | 1 | 2015 | 138 | 0.420 |
Why?
|
| Income | 1 | 2014 | 160 | 0.400 |
Why?
|
| Double-Blind Method | 4 | 2022 | 305 | 0.380 |
Why?
|
| Misoprostol | 6 | 2022 | 27 | 0.380 |
Why?
|
| Cesarean Section | 2 | 2011 | 63 | 0.370 |
Why?
|
| Balloon Occlusion | 1 | 2011 | 3 | 0.360 |
Why?
|
| Dilatation and Curettage | 1 | 2011 | 4 | 0.360 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2011 | 7 | 0.360 |
Why?
|
| Feeding Behavior | 1 | 2014 | 461 | 0.330 |
Why?
|
| Oxytocics | 3 | 2019 | 8 | 0.320 |
Why?
|
| Analgesics | 2 | 2022 | 55 | 0.320 |
Why?
|
| Logistic Models | 4 | 2022 | 1001 | 0.310 |
Why?
|
| Ultrasonography, Prenatal | 3 | 2024 | 40 | 0.300 |
Why?
|
| Diet | 1 | 2014 | 810 | 0.280 |
Why?
|
| Selenium | 2 | 2024 | 150 | 0.280 |
Why?
|
| Blood Loss, Surgical | 2 | 2018 | 15 | 0.270 |
Why?
|
| Pain | 2 | 2022 | 283 | 0.270 |
Why?
|
| Mifepristone | 3 | 2022 | 34 | 0.260 |
Why?
|
| Patient Satisfaction | 2 | 2017 | 163 | 0.250 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 3 | 2021 | 10 | 0.250 |
Why?
|
| Pregnancy Trimester, First | 2 | 2024 | 21 | 0.240 |
Why?
|
| Ibuprofen | 2 | 2022 | 34 | 0.230 |
Why?
|
| Students, Medical | 2 | 2018 | 153 | 0.230 |
Why?
|
| Health Priorities | 1 | 2025 | 25 | 0.230 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2025 | 6 | 0.230 |
Why?
|
| Child | 4 | 2024 | 3381 | 0.230 |
Why?
|
| Magnetics | 2 | 2022 | 43 | 0.220 |
Why?
|
| Pregnancy in Adolescence | 2 | 2016 | 34 | 0.210 |
Why?
|
| Women's Health | 1 | 2025 | 158 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 471 | 0.210 |
Why?
|
| Male | 14 | 2025 | 22779 | 0.210 |
Why?
|
| Physical Phenomena | 1 | 2023 | 3 | 0.210 |
Why?
|
| Treatment Outcome | 3 | 2024 | 1586 | 0.210 |
Why?
|
| Heating | 1 | 2023 | 6 | 0.210 |
Why?
|
| Body Temperature Regulation | 1 | 2023 | 8 | 0.210 |
Why?
|
| Elastomers | 1 | 2022 | 3 | 0.200 |
Why?
|
| Motion | 1 | 2022 | 30 | 0.190 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2022 | 4 | 0.190 |
Why?
|
| Aborted Fetus | 1 | 2022 | 5 | 0.190 |
Why?
|
| Pelvic Pain | 1 | 2022 | 10 | 0.190 |
Why?
|
| Parturition | 1 | 2022 | 22 | 0.180 |
Why?
|
| Intraoperative Complications | 2 | 2019 | 20 | 0.180 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 73 | 0.180 |
Why?
|
| Abortifacient Agents, Steroidal | 1 | 2021 | 3 | 0.180 |
Why?
|
| Drug and Narcotic Control | 1 | 2021 | 11 | 0.180 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 28 | 0.180 |
Why?
|
| Confidentiality | 1 | 2021 | 27 | 0.180 |
Why?
|
| Contraceptive Agents | 1 | 2020 | 13 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 577 | 0.170 |
Why?
|
| Infant, Newborn | 2 | 2022 | 960 | 0.160 |
Why?
|
| Sterilization, Tubal | 1 | 2020 | 6 | 0.160 |
Why?
|
| Macrophages | 1 | 2024 | 515 | 0.160 |
Why?
|
| Postoperative Complications | 2 | 2019 | 253 | 0.160 |
Why?
|
| Case-Control Studies | 2 | 2022 | 1266 | 0.160 |
Why?
|
| Drug Delivery Systems | 1 | 2022 | 273 | 0.160 |
Why?
|
| Electric Capacitance | 1 | 2019 | 7 | 0.160 |
Why?
|
| Textiles | 1 | 2019 | 7 | 0.160 |
Why?
|
| Foot | 1 | 2019 | 10 | 0.160 |
Why?
|
| Data Collection | 1 | 2019 | 210 | 0.150 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 25 | 0.150 |
Why?
|
| Middle Aged | 5 | 2025 | 11819 | 0.150 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2019 | 37 | 0.150 |
Why?
|
| Communication | 2 | 2017 | 207 | 0.150 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2018 | 33 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 147 | 0.140 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 3077 | 0.140 |
Why?
|
| Hemostatics | 1 | 2018 | 10 | 0.140 |
Why?
|
| Health Personnel | 1 | 2020 | 262 | 0.140 |
Why?
|
| Sodium Bicarbonate | 1 | 2017 | 7 | 0.140 |
Why?
|
| Retrospective Studies | 6 | 2024 | 2485 | 0.140 |
Why?
|
| Lidocaine | 1 | 2017 | 16 | 0.140 |
Why?
|
| Dilatation | 1 | 2017 | 4 | 0.130 |
Why?
|
| Age Factors | 2 | 2018 | 1139 | 0.130 |
Why?
|
| Delivery, Obstetric | 1 | 2017 | 48 | 0.130 |
Why?
|
| Self-Examination | 1 | 2017 | 9 | 0.130 |
Why?
|
| Decision Making | 1 | 2019 | 242 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2018 | 238 | 0.130 |
Why?
|
| Animals | 6 | 2024 | 16695 | 0.130 |
Why?
|
| Pamphlets | 1 | 2016 | 27 | 0.130 |
Why?
|
| Counseling | 3 | 2023 | 134 | 0.130 |
Why?
|
| Pain Measurement | 1 | 2017 | 181 | 0.130 |
Why?
|
| Sexual Partners | 1 | 2019 | 325 | 0.120 |
Why?
|
| Population Groups | 1 | 2016 | 59 | 0.120 |
Why?
|
| Parents | 2 | 2016 | 359 | 0.120 |
Why?
|
| Trust | 1 | 2017 | 157 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2017 | 99 | 0.120 |
Why?
|
| Family Relations | 1 | 2015 | 46 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2018 | 733 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1051 | 0.110 |
Why?
|
| Family Characteristics | 1 | 2015 | 124 | 0.110 |
Why?
|
| Philippines | 1 | 2014 | 80 | 0.110 |
Why?
|
| Pacific Islands | 1 | 2014 | 121 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 744 | 0.100 |
Why?
|
| Focus Groups | 1 | 2015 | 398 | 0.100 |
Why?
|
| Japan | 1 | 2014 | 348 | 0.100 |
Why?
|
| Overweight | 1 | 2015 | 248 | 0.100 |
Why?
|
| Selenoproteins | 1 | 2015 | 146 | 0.100 |
Why?
|
| Vaccination | 1 | 2015 | 332 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2015 | 359 | 0.100 |
Why?
|
| Social Support | 1 | 2015 | 438 | 0.100 |
Why?
|
| Obesity | 2 | 2017 | 1131 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 107 | 0.090 |
Why?
|
| Vitamin D | 1 | 2013 | 196 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 979 | 0.080 |
Why?
|
| Health Promotion | 1 | 2016 | 691 | 0.080 |
Why?
|
| Fishes | 2 | 2024 | 59 | 0.080 |
Why?
|
| Pregnancy Outcome | 1 | 2010 | 92 | 0.080 |
Why?
|
| Placenta | 2 | 2024 | 113 | 0.080 |
Why?
|
| Neoplasms | 1 | 2018 | 1341 | 0.070 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2025 | 5 | 0.060 |
Why?
|
| Eligibility Determination | 1 | 2024 | 9 | 0.060 |
Why?
|
| Pregnancy, Ectopic | 1 | 2024 | 15 | 0.060 |
Why?
|
| Phantoms, Imaging | 1 | 2024 | 27 | 0.050 |
Why?
|
| Abortion, Legal | 1 | 2023 | 6 | 0.050 |
Why?
|
| Selenocysteine | 1 | 2024 | 54 | 0.050 |
Why?
|
| Flowers | 1 | 2023 | 20 | 0.050 |
Why?
|
| Pharmacists | 1 | 2024 | 56 | 0.050 |
Why?
|
| Asia | 1 | 2023 | 99 | 0.050 |
Why?
|
| Cysteine | 1 | 2024 | 101 | 0.050 |
Why?
|
| Gender Identity | 1 | 2024 | 117 | 0.050 |
Why?
|
| Holistic Health | 1 | 2023 | 13 | 0.050 |
Why?
|
| Electricity | 1 | 2022 | 12 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2024 | 180 | 0.050 |
Why?
|
| Oxycodone | 1 | 2022 | 7 | 0.050 |
Why?
|
| Acetaminophen | 1 | 2022 | 28 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2023 | 137 | 0.050 |
Why?
|
| Locomotion | 1 | 2022 | 104 | 0.050 |
Why?
|
| Mice | 2 | 2024 | 6490 | 0.040 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2021 | 4 | 0.040 |
Why?
|
| Microtechnology | 1 | 2021 | 6 | 0.040 |
Why?
|
| Biomimetics | 1 | 2021 | 14 | 0.040 |
Why?
|
| Aftercare | 1 | 2021 | 22 | 0.040 |
Why?
|
| Biomimetic Materials | 1 | 2021 | 24 | 0.040 |
Why?
|
| Equipment Design | 1 | 2021 | 143 | 0.040 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2020 | 12 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 245 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 362 | 0.040 |
Why?
|
| Blood Volume | 1 | 2019 | 6 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 207 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 25 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2023 | 467 | 0.040 |
Why?
|
| Methylergonovine | 1 | 2018 | 3 | 0.040 |
Why?
|
| Vasopressins | 1 | 2018 | 13 | 0.040 |
Why?
|
| Minority Groups | 1 | 2023 | 663 | 0.040 |
Why?
|
| Gynecology | 1 | 2018 | 33 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2017 | 18 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 336 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2019 | 574 | 0.030 |
Why?
|
| Obstetrics | 1 | 2018 | 41 | 0.030 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2017 | 5 | 0.030 |
Why?
|
| Parity | 1 | 2017 | 60 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 2598 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 61 | 0.030 |
Why?
|
| Prevalence | 2 | 2013 | 1597 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 146 | 0.030 |
Why?
|
| Sex Education | 1 | 2016 | 36 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1020 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 152 | 0.030 |
Why?
|
| Community Networks | 1 | 2016 | 106 | 0.030 |
Why?
|
| Health Surveys | 1 | 2017 | 401 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 237 | 0.030 |
Why?
|
| Peer Group | 1 | 2016 | 173 | 0.030 |
Why?
|
| Time Factors | 1 | 2019 | 1848 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 358 | 0.030 |
Why?
|
| Adolescent Behavior | 1 | 2016 | 270 | 0.030 |
Why?
|
| Health Education | 1 | 2016 | 358 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 35 | 0.020 |
Why?
|
| Lactation | 1 | 2013 | 44 | 0.020 |
Why?
|
| Sunlight | 1 | 2013 | 48 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 884 | 0.020 |
Why?
|
| Seasons | 1 | 2013 | 133 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2016 | 634 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 236 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2013 | 208 | 0.020 |
Why?
|
| Maternal Age | 1 | 2010 | 34 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 1265 | 0.020 |
Why?
|
| Micronesia | 1 | 2010 | 87 | 0.020 |
Why?
|
| Birth Weight | 1 | 2010 | 94 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 249 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 1143 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1221 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 1574 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2010 | 386 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2010 | 916 | 0.020 |
Why?
|
| Aged | 1 | 2016 | 7982 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 3942 | 0.010 |
Why?
|